UCB SA (OTCMKTS:UCBJY – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $95.59 and traded as low as $81.63. UCB shares last traded at $81.73, with a volume of 39,804 shares changing hands.
UCB Stock Down 7.5 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $96.07 and a 200 day moving average of $95.64.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
- Five stocks we like better than UCB
- What Do S&P 500 Stocks Tell Investors About the Market?
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- Airline Stocks – Top Airline Stocks to Buy Now
- Disney 2025 Shareholders: Major Updates for Investors
- What Are Dividend Champions? How to Invest in the Champions
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
